Peptide library

MOTS-c

A 16-amino-acid peptide encoded in mitochondrial DNA, described in 2015. The studies that gave it are in mice and cells; the human studies so far measured the body’s own levels.

Short answerCompound research · 5 min read · Updated 18 Nov 2026

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene, first described in 2015. Studies that gave it were in mice and cells; human studies have measured only the body’s own levels. A placebo-controlled phase 2a trial is recruiting. It is not an approved medicine, and WADA prohibits it at all times.

Key takeaways

  • MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene, described by a University of Southern California group in 2015.
  • Studies that gave MOTS-c were in mice and cells; human studies so far measured natural levels, for example after exercise.
  • A placebo-controlled phase 2a trial began in February 2026 and has no results.
  • FDA says it has no human exposure data for MOTS-c; HHS cites a trial of an unnamed analogue that reported no serious adverse events.
  • WADA names it in class S4.4.1, prohibited at all times.

01MOTS-c at a glance

The short version, dated 18 November 2026. Every line is sourced at the end of the page.

QuestionMOTS-c
What it isA 16-amino-acid peptide, MRWQEMGYIFYPRKLR, encoded by a short open reading frame inside the mitochondrial 12S rRNA gene. Described in 2015.
Other namesMitochondrial open reading frame of the 12S rRNA-c, the source of the name. Written “MOTs-C” on FDA’s compounding page. A mitochondrial-derived peptide, like humanin.
Evidence tierT3 (mouse) and T4 (cell) for studies that gave it. T2 for human studies that measured the body’s own levels.
Human studiesNone published that gave MOTS-c itself to people (PubMed and ClinicalTrials.gov, 18 Nov 2026). One registered: phase 2a, randomised, placebo-controlled, estimated n=120, recruiting, no results.
United StatesNot FDA-approved. In FDA’s compounding Category 2 from 29 Sep 2023 to 22 Apr 2026, now listed as a nomination withdrawn. Named in HHS’s draft enforcement-discretion policy for licensed compounders (Federal Register notice, 30 Oct 2026), which is not binding and not an approval.
United KingdomNo UK-licensed medicine found on the emc database (18 Nov 2026).
AustraliaNot named in the Poisons Standard October 2026 (text searched 18 Nov 2026); we found no TGA statement applying any of its group entries to it and draw no scheduling conclusion of our own.
WADAProhibited at all times, class S4.4.1, metabolic modulators, named among activators of AMPK (2026 and 2027 Lists).

02What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene. Most of the body’s proteins are encoded in the cell nucleus. Mitochondria, the compartments that produce most of a cell’s energy, carry their own small genome. In 2015, a group at the University of Southern California reported a short open reading frame inside the mitochondrial 12S rRNA gene that encodes a 16-amino-acid peptide, and named it MOTS-c.

In cell and mouse work, the same paper proposed skeletal muscle as its main target and a mechanism that runs through folate metabolism to AMPK, an enzyme that senses a cell’s energy state (T4). The body makes MOTS-c on its own, and it can be measured in blood and muscle. Our MOTS-c research overview covers the same studies in brief.

03How has MOTS-c been studied, and in what models?

Studies that gave MOTS-c were in mice and cells; human studies so far measured natural levels, for example after exercise.

Mice, 2015 (T3). The paper that described MOTS-c gave it to mice on a high-fat diet and to ageing mice, and measured insulin resistance and weight gain. The authors reported less insulin resistance in both groups, and less weight gain on the high-fat diet, in mice given MOTS-c. These are mouse results; the abstract does not give the number of animals.

Mice of different ages, 2021 (T3). The same group reported that MOTS-c increased measures of physical capacity in young, middle-aged and old mice. In the same paper, exercise raised the body’s own MOTS-c in human muscle and blood. Two authors declared consulting roles and shares in CohBar, Inc.

People: natural levels (T2). Human studies so far measured MOTS-c the body makes, for example before and after exercise. Studies like these show when levels change, not what giving MOTS-c does.

People: the first trial (registered). NCT07505745 is a phase 2a, randomised, placebo-controlled trial planned for 120 adults with prediabetes and overweight or obesity. Its primary outcomes are an insulin-sensitivity index from a glucose-tolerance test, and adverse events. It began in February 2026 and is recruiting, with no results.

An analogue. HHS’s 2026 policy appendix cites “a randomized placebo-controlled trial of a MOTS-c analogue” that “reported no serious adverse events”. The appendix does not name the analogue or the trial, and an analogue is a different molecule. FDA staff, reviewing MOTS-c for the July 2026 advisory committee, found no clinical studies or human exposure data for MOTS-c itself.

04What have regulators said about MOTS-c safety?

We found no controlled human safety study of MOTS-c itself (18 Nov 2026), and neither of the regulator statements below contains one.

FDA. FDA’s compounding page says MOTS-c products “may pose significant risk for immunogenicity for certain routes of administration”, that FDA “has not identified any human exposure data” for MOTS-c by any route, and that it lacks information on “whether it would cause harm if administered to humans”. FDA staff found no reports in FAERS, its adverse-event database, through 9 March 2025, and concluded that “potential safety risks associated with the use of MOTS-c in humans are unknown”. They also found no nonclinical toxicity studies of MOTS-c, and a laboratory study reporting that it is quickly broken down in human blood.

HHS. HHS read the record differently. Its appendix says “the available safety evidence points in one direction”, citing the analogue trial and rodent studies that, it says, showed no systemic toxicity.

How to read safety claims like these: side effects, documented vs unknown.

05Is MOTS-c an approved medicine? Status by country

United States. MOTS-c is not an FDA-approved drug. HHS records that it sat in FDA’s compounding Category 2 from 29 September 2023 to 22 April 2026, that FDA staff recommended against adding it to the 503A bulks list, and that the July 2026 advisory committee voted in favour. HHS then named MOTS-c among six peptides in a policy saying it does not intend to pursue enforcement against state-licensed pharmacies, federal facilities and licensed physicians compounding with them, under conditions that include a patient-specific prescription. The Federal Register notice of 30 October 2026 calls it a draft that “is not binding”. It is not an approval. Background: the July 2026 vote and the HHS policy.

United Kingdom. A search of the emc medicines database for MOTS-c returned no results on 18 November 2026. FDA’s 2026 briefing found no MOTS-c product authorised by the European Medicines Agency.

Australia. MOTS-c is not named in the Poisons Standard October 2026, and we found no TGA statement applying any of its group entries to it; we draw no scheduling conclusion of our own. Other Australian rules on unapproved peptide products are covered in are peptides legal in Australia?

Sport. WADA names MOTS-c in class S4.4.1, metabolic modulators, among activators of AMPK. It is prohibited at all times in the 2026 List and in the 2027 List, in force from 1 January 2027. See peptides and anti-doping.

06What doesn’t MOTS-c research show?

  • Any effect of giving MOTS-c to people. No such study has published results; the first placebo-controlled trial is recruiting.
  • That the mouse results apply to people. They have not been tested in a completed human trial.
  • What natural MOTS-c levels mean for health. Level studies show changes and associations, not cause and effect.
  • That the two best-known mouse studies are independent of commercial interest. Both come from the group that discovered MOTS-c; in 2021, two of its members declared consulting roles and shares in CohBar, Inc.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. Lee C, Zeng J, Drew BG, et al. [Description of MOTS-c, with cell and mouse experiments on metabolism.] Cell Metab, 2015;21(3):443–454. PMID 25738459. pubmed.ncbi.nlm.nih.gov/25738459/
  2. Reynolds JC, Lai RW, Woodhead JST, et al. [MOTS-c in mice of different ages, and natural MOTS-c levels in exercising men.] Nat Commun, 2021;12(1):470. PMID 33473109. pubmed.ncbi.nlm.nih.gov/33473109/
  3. ClinicalTrials.gov. NCT07505745: phase 2a, randomised, placebo-controlled study of MOTS-c in adults with prediabetes and overweight or obesity. Registry record, first posted 1 Apr 2026; read 18 Nov 2026. clinicaltrials.gov/study/NCT07505745
  4. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  5. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: MOTS-c-related bulk drug substances. Advisory committee briefing, 2026 (pp. 21, 28–29). www.fda.gov/media/193347/download
  6. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. Policy document, 2026. hhs.gov returned 403 to our fetch on 18 Nov 2026; read on the Internet Archive capture of 15 Nov 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…
  7. Federal Register 91 FR 68526, FR Doc. 2026-22192. Notice of availability: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Notice, 30 Oct 2026; text read on govinfo 18 Nov 2026. www.federalregister.gov/documents/2026/10/30/2026-22192/enfo…
  8. World Anti-Doping Agency. Prohibited List 2026 (in force 1 Jan 2026) and Prohibited List 2027 (in force 1 Jan 2027). International Standard; both PDFs read 18 Nov 2026. www.wada-ama.org/en/prohibited-list
  9. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327), Schedule 4 and Appendix D. Federal Register of Legislation, registered 30 Sep 2026, commenced 1 Oct 2026; read 18 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  10. emc (electronic medicines compendium). Search for “MOTS-c”: no results. UK database of licensed medicines, searched 18 Nov 2026. www.medicines.org.uk/emc/search?q=MOTS-c

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

What is MOTS-c?

A 16-amino-acid peptide encoded in mitochondrial DNA, inside the 12S rRNA gene, first described in 2015. The body makes it, and researchers have measured it in blood and muscle.

Has MOTS-c been tested in humans?

Not as a given substance in any published study we found. A placebo-controlled phase 2a trial began in February 2026, and earlier human studies measured the body’s own MOTS-c levels.

Is MOTS-c FDA-approved?

No. HHS named it in a draft 2026 enforcement-discretion policy for licensed pharmacies and physicians who compound it, which is not binding and is not an approval.

Is MOTS-c prohibited in sport?

Yes. WADA names it in class S4.4.1, metabolic modulators, prohibited at all times in the 2026 and 2027 Lists.

Is MOTS-c the same as humanin?

No. Both are peptides encoded in mitochondrial DNA, but they are different molecules with different sequences.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page
Further reading

Articles on this topic

Comparison5-amino-1MQ vs MOTS-c: identity, evidence and status5-amino-1MQ is a small molecule; MOTS-c is a mitochondrial peptide. Their evidence, human data, regulatory records and anti-doping status differ.10 min readSport · WADAIs MOTS-c Banned in Sport? WADA S4.4.1 and Dates (2026)Yes. WADA has named MOTS-c in class S4.4.1, prohibited at all times, since the 2025 List. The List text, what non-Specified means, TUEs and 2027.9 min readLegal status · AustraliaIs MOTS-c Legal in Australia? TGA, Law and Dates (2026)The Poisons Standard does not name MOTS-c, but the TGA says supplying unapproved peptide products is unlawful. The Act, the 2026 record and sport.10 min readLegal status · UKIs MOTS-c Legal in the UK? MHRA, Law and Dates (2026)We found no UK law that names MOTS-c, and medicines law still applies. The Human Medicines Regulations 2012, MHRA guidance, the 2026 record and sport.11 min readLegal status · USIs MOTS-c Legal in the US? FDA Status and Dates (2026)MOTS-c is not FDA-approved or on the 503A bulks list, and a draft HHS compounding policy of October 2026 names it. FDA’s category history and dates.11 min readClaims vs evidenceMOTS-c Claims vs Evidence: Mouse Data, No Human ResultsClaims about MOTS-c rest on mouse and cell studies: the model, sample and tier behind each. No published study has given it to people; one trial is…10 min readLab literacyMOTS-c COA: what a certificate of analysis should showA MOTS-c COA identifies the batch, tests, methods, limits, results, date, and responsible lab. Identity and purity results answer different questions.7 min readSafety recordMOTS-c side effects: what has been reported, and by whomMOTS-c has no established human safety profile. See what a registered trial plans to measure, what FDA found, and whom the trial excludes.7 min readComparisonMOTS-c vs NAD+: identity, evidence and legal statusMOTS-c is a 16-amino-acid peptide; NAD+ is a coenzyme. Compare the evidence and the limits of what US, UK, Australian and sport-status checks show.9 min readComparisonMOTS-c vs SLU-PP-332: identity, evidence and legal statusMOTS-c is a 16-amino-acid peptide; SLU-PP-332 is a small synthetic molecule, not a peptide. Studies that gave either used cells and animals (21 Nov…13 min readComparisonMOTS-c vs SS-31: identity, evidence and legal statusMOTS-c and SS-31 are distinct peptides. Compare their identity, human evidence, U.S. regulatory status, and WADA listings.8 min readStudy explainerWho was in the MOTS-c studies: sex, age and exclusionsMOTS-c human study populations: what is known about sex, age, pregnancy and exercise eligibility—and what has not been studied.6 min read